What we do Sanofi India Ltd is a leading multinational pharmaceutical company in India engaged in manufacturing and marketing prescription drugs, focusing on diabetes, cardiovascular and CNS therapies. |
Founded in 1,956 |
Market share Strong market leader in insulin with 31% share and top 100 pharmaceutical brands in India including Lantus and Combiflam. |
Problem solved Addressing diabetes, cardiovascular, central nervous system diseases, and providing effective pharmaceutical treatments and healthcare solutions. |
Top clients or who we serve Serves healthcare professionals, hospitals, and consumers primarily in India, focusing on B2B and B2C pharmaceutical markets. |
Key management Eric Mansion - Non-Executive Director; Rachid Ayari - CFO; Renee Amonkar - Whole-time Director; Rodolfo Hrosz - Managing Director (till April 2025). |
Our journey and innovations Since 1956, evolved from Aventis Pharma to Sanofi India; launched iconic insulin Lantus and innovative products like Toujeo and reusable insulin pens. |
Where we operate Primarily India with export operations to Singapore and other countries. |
Top products or what we offer Flagship brands include Lantus (insulin), Combiflam (pain relief), Amaryl (diabetes), Allegra (allergy), Toujeo (insulin). |
Top brands Lantus - #1 insulin brand; Combiflam - iconic pain relief; Amaryl - leading anti-diabetic; Allegra - popular allergy brand; Toujeo - advanced insulin. |
Raw materials needed Active pharmaceutical ingredients, chemical compounds required for drug manufacturing. |
Raw materials supplier Supplied by global and domestic pharmaceutical raw material suppliers ensuring quality compliance. |
Recurring vs cyclical contribution Revenue mainly recurring from pharmaceutical sales with some cyclical elements based on market demand. |
Our industry position Among top pharmaceutical companies in India with significant share in diabetes care and leading legacy brands. |
Financial highlights FY24 revenue ₹2013 crore with ₹413 crore net profit; stable domestic growth and margin expansion. |
Geographical revenue split 80% revenue from India, 19% from Singapore, remaining 1% from other countries. |
Order book - |
Whats driving growth Growth driven by diabetes portfolio, insulin franchise expansion, operational efficiency and strategic partnerships. |
Our future plans Focus on insulin business, diabetes innovation, digital capabilities and growing legacy cardiovascular and CNS brands. |
Our green promise Committed to corporate social responsibility with health awareness programs and sustainability initiatives. |
Our people and values Employee centric culture with focus on diversity and ethical governance. |
Key challenges ahead Managing regulatory changes, competition, and supply chain risks amid evolving market dynamics. |
Interesting facts Sanofi India launched India's first reusable insulin pen, along with pioneering several innovative diabetes treatments. |
Risks and strategy Mitigating regulatory and market risks through diversification, R&D investment, and strategic partnerships. |
